Mercury Bio

Executive Summary

Mercury Bio is a private, pre-clinical biotechnology company based in San Diego, founded in 2021. The company is pioneering intracellular immunotherapeutics for neurodegenerative diseases, with an initial focus on Parkinson’s and Alzheimer’s. Its core technology, MB-TIP™, is a patented drug delivery platform designed to transport large therapeutic molecules across the blood-brain barrier and directly into the cytoplasm of target cells, addressing a major limitation in treating diseases that originate inside cells. By enabling precise intracellular delivery, Mercury Bio aims to unlock new treatment modalities for conditions with high unmet need. Currently in the pre-clinical stage, Mercury Bio is advancing its lead candidates through in vivo studies and preparing for regulatory interactions. The company's differentiated platform has the potential to revolutionize the treatment of neurodegenerative disorders by targeting pathological proteins at their source within cells. While still early-stage, the strong scientific rationale and novel delivery approach position Mercury Bio for potential partnerships and milestone-driven growth. The company's next key milestones include completion of IND-enabling studies, presentation of preclinical data at major conferences, and progress toward a first-in-human trial.

Upcoming Catalysts (preview)

• H2 2027IND filing for lead program in Parkinson's disease40% success
• Q4 2026Presentation of preclinical in vivo efficacy data at a major neurodegeneration conference70% success
• TBDStrategic partnership or licensing deal for MB-TIP platform in an additional indication30% success